Israeli biotech Kamada (see here) has partnered Italy’s Kedrion to develop a human plasma-derived Anti-SARs-COV-2 product. Kamada will use its proprietary IgG platform technology and Kedrion will provide plasma from donors who have recovered from the virus.
https://www.kedrion.com/kedrion-and-kamada-announce-collaboration-anti-covid-19-igg-0